| Transaction Date | Recipient | Shares | Type | Price | Value |
|---|---|---|---|---|---|
| 5th January 2021 | Mark E Saad | 8,227 | Grant/award etc. | $0.00 | |
| 18th November 2020 | Roger Jeffs | 1,387,500 | Other acquisition or disposition | $6.00 | $8,325,000.00 |
| 12th October 2020 | Mark E Saad | 100,000 | Grant/award etc. | $0.00 | |
| 19th August 2020 | Mark Coleman | 397,998 | Bona fide gift | $0.00 | |
| 19th August 2020 | Mark Coleman | 397,998 | Bona fide gift | $0.00 | |
| 29th June 2020 | Nick Pizzie | 777 | Open or private purchase | $76.64 | $59,549.28 |
| 29th June 2020 | Mark Coleman | 650 | Open or private purchase | $78.50 | $51,025.00 |
| 10th January 2020 | Roger Jeffs | 11,000 | Exercise of derivative | $4.95 | $54,450.00 |
| 10th January 2020 | Roger Jeffs | 9,127 | Exercise of derivative | $9.00 | $82,143.00 |
| 10th January 2020 | Roger Jeffs | 34,866 | Exercise of derivative | $12.95 | $451,514.70 |
Axsome Therapeutics
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 10/10.
Axsome Therapeutics, Inc. is a clinical stage biopharmaceutical company. The company was founded by Herriot Tabuteau on January 12, 2012.
Ticker: AXSM
Sector: Health Technology
Industry: Pharmaceuticals: Other
SEC Central Index Key (CIK): 1579428
Employees: 45
Exchange: NASDAQ
Auditor Opinion:
You must Login to see Language Changes
Disclosure Language changes
You must Login to see analysis
Red Flags
There were no Red Flags found
Fundamentals
Assets, Current: $191 M (-13%)
Property, Plant and Equipment, Net: $30 Th (0%)
Other Assets, Noncurrent: $140 Th (0%)
Assets: $191 M (-13%)
Long-term Debt, Current Maturities: $7 M (0%)
Accounts Payable, Current: $9 M (-14%)
Liabilities, Current: $23 M (-6%)
Long-term Debt, Excluding Current Maturities: $14 M (0%)
Liabilities: $37 M (-12%)
Common Stock, Value, Issued: $4 Th (0%)
Common Stock, Shares, Issued: $37 M (0%)
Retained Earnings (Accumulated Deficit): $227 M (0%)
Stockholders' Equity (Parent): $154 M (0%)
Liabilities and Equity: $191 M (-13%)
Research and Development: $11 M (-72%)
General and Administrative Expenses: $7 M (-40%)
Operating Income/Loss: $18 M (-64%)
